Immix Biopharma, Inc. expected to post a loss of 18 cents a share - Earnings Preview

Immix Biopharma

04/08/2026 21:55

Immix Biopharma, Inc. IMMX.OQ IMMX.O is expected to  report resultson August 6 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Immix Biopharma, Inc. is for a loss of 18 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Immix Biopharma, Inc. is $20.00, about 137.5% above its last closing price of $8.42
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.21
-0.21
-0.18
Beat
13.6
Dec. 31 2026
-0.16
-0.16
-0.28
Missed
-79.5
Sep. 30 2025
-0.19
-0.19
-0.24
Missed
-26.3​
Jun. 30 2025
-0.16
-0.16
-0.22
Missed
-37.5
​​Mar. 31 2025
-0.23
-0.15
Beat
34.8
Dec. 31 2024
-0.25
-0.25
-0.16
Beat
36​
Sep. 30 2024
-0.16
-0.16
-0.24
Missed
-50
Jun. 30 2024
-0.21
-0.21
-0.15
Beat
28.6
This summary was machine generated August 4 at 20:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)